Altimmune, Inc. (NASDAQ:ALT) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Altimmune, Inc. (NASDAQ:ALT) has earned an average rating of “Moderate Buy” from the eight ratings firms that are presently covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among analysts that have covered the stock in the last year is $20.00.

ALT has been the subject of a number of research reports. B. Riley reiterated a “buy” rating and issued a $20.00 price target on shares of Altimmune in a research note on Monday, August 12th. Evercore ISI raised shares of Altimmune to a “strong-buy” rating in a report on Friday, August 9th. UBS Group assumed coverage on Altimmune in a research note on Tuesday, November 12th. They set a “buy” rating and a $26.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Altimmune in a research note on Thursday.

Institutional Trading of Altimmune

Hedge funds have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Altimmune in the 1st quarter valued at about $271,000. BNP Paribas Financial Markets lifted its position in Altimmune by 154.0% in the 1st quarter. BNP Paribas Financial Markets now owns 32,425 shares of the company’s stock worth $330,000 after buying an additional 19,661 shares in the last quarter. SG Americas Securities LLC boosted its stake in shares of Altimmune by 68.3% during the 1st quarter. SG Americas Securities LLC now owns 39,603 shares of the company’s stock valued at $403,000 after buying an additional 16,078 shares during the period. Swiss National Bank purchased a new position in Altimmune in the first quarter valued at about $1,079,000. Finally, Sei Investments Co. acquired a new position in Altimmune in the 1st quarter worth about $479,000. Hedge funds and other institutional investors own 78.05% of the company’s stock.

Altimmune Stock Down 9.9 %

NASDAQ ALT opened at $7.61 on Monday. The business has a 50 day moving average price of $7.02 and a two-hundred day moving average price of $6.91. The stock has a market cap of $541.22 million, a PE ratio of -4.91 and a beta of 0.09. Altimmune has a fifty-two week low of $2.34 and a fifty-two week high of $14.84.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.03. The firm had revenue of $0.01 million during the quarter. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. During the same quarter last year, the business earned ($0.39) EPS. Sell-side analysts anticipate that Altimmune will post -1.36 EPS for the current fiscal year.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.